桂林三金药业股份有限公司投资者关系活动记录表 编号：2025018 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | | □新闻发布会 ☑路演活动 | | | □现场参观 | | | □其他 | | 活动参与人员 | 东方财富证券 易方达基金 天厚基金 深圳抱朴容易资产 5 人 桂林三金董秘 李春 | | | 桂林三金证代 朱烨 | | 时间 | 2025 年 06 月 25 日 | | | 会议室 | | 地点 形式 | 线下交流 | | | 1、目前西瓜霜系列和三金片系列的库存情况怎么样？ | | | 近年来，公司围绕库存管理体系升级持续发力，依托 BI | | | 智能分析系统，组建专业数据分析团队，通过构建科学的 | | | "成品库存标准模型"，精准锚定市场需求动态与成本控 | | | 制的平衡点。借助精细化的库存管理策略，实现库存周转 | | | 效率的有效提升。同时，公司创新推出多元化促销活动， | | | 有效激活终端消费市场，推动全渠道库存结构优化。目前， | | | 公司不仅实现自身库存的高效管控，更带动渠道 ...

Financial Performance - In 2024, the company achieved total revenue of CNY 2,193.99 million, a growth of 1.03% compared to CNY 2,171.60 million in the previous year [1] - The total profit reached CNY 643.94 million, marking a 24.24% increase from CNY 518.28 million year-on-year [1] - Net profit attributable to shareholders was CNY 521.53 million, up 23.79% from CNY 421.30 million in the previous year [1] - In Q1 2025, the net profit after deducting non-recurring gains and losses was CNY 97.67 million, an increase of 11.61% from CNY 87.52 million in the same period last year [1] Business Strategy and Market Conditions - The biopharmaceutical sector is a key component of the company's dual-wing strategy, facing a challenging environment with high investment and long R&D cycles [1] - The industry is currently experiencing a downturn, with increased competition and diverse customer choices impacting business operations [1] - The company is focusing on cost control and optimizing employee structure to mitigate losses while continuing to invest in R&D [1] - Key projects, such as the BC006 monoclonal antibody injection, are progressing, with Phase I clinical trials nearing completion [1] Sales and Marketing Strategy - The company maintains strict control over sales expenses, with a focus on precision and targeted investment [2] - Sales expenses are being directed more towards second and third-tier products, with adjustments based on market performance [2] - The growth potential for second and third-tier products remains strong, with specific products like the Hagei Ding Chuan capsule expected to continue their growth trajectory [2] - The company aims to maintain a stable sales expense ratio in line with sales revenue [2] Dividend Policy - The company is committed to providing stable returns to investors, maintaining a consistent cash dividend policy since its listing [2] - For the 2024 fiscal year, the proposed dividend is CNY 3.5 per 10 shares, totaling CNY 206 million in cash dividends [2] - The company plans to continue its cash dividend strategy for the mid-2025 period, barring any special funding needs [2]

5月22日，翔宇医疗参与河南辖区上市公司2025年投资者网上集体接待日。期间管理层介绍，翔宇医疗深耕大康复"全 赛道"二十多年，公司基于专病专科临床需求和康复市场发展需要，持续研发、优化临床所需的康复装备，完善专病 专科及全院临床康复一体化解决方案。在优势领域精耕细作的同时，将在康复机器人、脑机接口、AI医疗、精神心 理、心肺康复等领域推出更多满足临床需求和医康养护市场需求的产品及解决方案。 仁和药业：委外生产的初衷是丰富在销品种的品类品规 5月21日，仁和药业参与江西辖区上市公司投资者网上集体接待日。期间管理层介绍，公司委外生产产品的初衷就是 丰富公司在销品种的品类品规，原则上是与公司产品互补且公司没有批文的，或者是公司产能不够的品种。这些委外 产品经公司商业公司销售后，其收入与利润全部体现在公司的财表中。 华兰生物：正对重组人血白蛋白各种生产表达系统进行对比评估 5月22日，华兰生物参与河南辖区上市公司2025年投资者网上集体接待日。期间管理层介绍，目前国内主要有三家企 业开展重组人血白蛋白的研发，截止目前均未取得《药品注册证书》，未获批上市，后续若获准上市且产品质量稳 定、成本可控，可适当缓解国内人白供 ...

Group 1 - The core revenue of the company primarily comes from traditional Chinese medicine, with contributions from chemical drugs and daily health products [1] - The company is focusing on expanding its sales channels for its watermelon frost toothpaste series, which includes various products and is currently being promoted in second-tier and lower cities [1] - The company plans to leverage its brand recognition and capital market advantages to strengthen its market position in daily health products [1] Group 2 - The overall development trend for the company's second and third-tier products is positive, with continued support for these products [2] - The company aims for double-digit growth in the sales of the dizziness relief series, which surpassed 100 million yuan in sales in 2021 [2] - The losses from the large pharmacy chain are attributed to significant expansion costs, and the chain is currently focused on the Guilin area to enhance the company's marketing strategy and sales channels [2]